Share: Share on Facebook Share on Twitter Share on LinkedIn I recommend visiting to read:%0A%0A {0} %0A%0A {1}
Life Sciences Golden Triangle Report Life Sciences Golden Triangle Report

Life Sciences: Golden Triangle Report

Jamie Renison • 01/02/2023

The life sciences sector continued to experience rapid expansion in 2022, with underlying growth trends luring both new and seasoned investors into the market. At the beginning of 2022, Big Pharma reportedly had more than $1.7tn (£1.4tn) in dry powder set aside for the expansion of their IP pipeline. However, 2022 turned out to be a rather mild year for M&A activity, with $65bn (£54bn) in transactions among the top 10 pharmaceutical companies. The amount of venture capital raised was also lower than the record year of 2021, yet it was still 22% higher than 2020 levels. 

Looking ahead, the demand from biotech occupiers for lab space remains strong and will continue to outstrip supply. We expect further delays in new starts, compounding the imbalance, despite a number of schemes reportedly forecast for delivery in 2025/26. 
Inside our latest Life Sciences Lab Report you’ll find insight on investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, London, and Oxford throughout 2022.  

Key Takeaways: 

  • Investment volumes reached £2.4bn in 2022
  • Leasing take-up for the year in the Golden Triangle reached 635,866 sq ft
  • London accounted for 39% of all life science leasing activity in the Golden Triangle; 
  • A lack of purpose-built life sciences space limited leasing volumes in 2022; 
  • Within the core Golden Triangle locations, supply increased by 350,000 sq ft in 2022
  • It's not until 2025/26 that we expect to see approximately four million sf ft of supply delivered
  • Level of venture capital raised across UK life sciences companies, exceeded all years except 2021


GSK Completes Sale Of Strategic Life Sciences Development Site

Real estate services firm Cushman & Wakefield has advised GSK plc on the sale of the surplus development land that sits alongside its 1 million sq ft Research & Development (R&D) facility in Stevenage to UBS Asset Management and Reef Group. 


Life Science
Research • Lab

Life Sciences Update: October 2022

Following extraordinary investment, expansion, and innovation in 2021, the life sciences industry is poised for further growth and consistent demand in the years ahead.
Sandy Romero • 26/10/2022
Life Sciences Real Estate Services
We help life science companies create flexible real estate strategies to attract and retain top talent, while managing efficiency and costs.
Learn More

Ready to talk?

Get in touch with one of our professionals.
With your permission we and our partners would like to use cookies in order to access and record information and process personal data, such as unique identifiers and standard information sent by a device to ensure our website performs as expected, to develop and improve our products, and for advertising and insight purposes.

Alternatively click on More Options and select your preferences before providing or refusing consent. Some processing of your personal data may not require your consent, but you have a right to object to such processing.

You can change your preferences at any time by returning to this site or clicking on Cookies.
Agree and Close
These cookies ensure that our website performs as expected,for example website traffic load is balanced across our servers to prevent our website from crashing during particularly high usage.
These cookies allow our website to remember choices you make (such as your user name, language or the region you are in) and provide enhanced features. These cookies do not gather any information about you that could be used for advertising or remember where you have been on the internet.
These cookies allow us to work with our marketing partners to understand which ads or links you have clicked on before arriving on our website or to help us make our advertising more relevant to you.
Agree All
Reject All